CN103637179A - Food composition with functions of lowering blood sugar and blood fat and improving fatty liver - Google Patents
Food composition with functions of lowering blood sugar and blood fat and improving fatty liver Download PDFInfo
- Publication number
- CN103637179A CN103637179A CN201310469837.6A CN201310469837A CN103637179A CN 103637179 A CN103637179 A CN 103637179A CN 201310469837 A CN201310469837 A CN 201310469837A CN 103637179 A CN103637179 A CN 103637179A
- Authority
- CN
- China
- Prior art keywords
- food composition
- parts
- fatty liver
- blood
- hypoglycemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 71
- 239000008280 blood Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 235000013305 food Nutrition 0.000 title claims abstract description 29
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 23
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 23
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 22
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 22
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 12
- 241001598107 Imperata Species 0.000 claims abstract description 10
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 235000021013 raspberries Nutrition 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 150000002632 lipids Chemical class 0.000 claims description 16
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 13
- 241001092040 Crataegus Species 0.000 claims description 11
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 11
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 11
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 11
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 11
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 11
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 11
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 11
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 11
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 11
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 11
- 244000241838 Lycium barbarum Species 0.000 claims description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 10
- 240000003582 Platycodon grandiflorus Species 0.000 claims description 9
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 9
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 239000008103 glucose Substances 0.000 abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 244000025254 Cannabis sativa Species 0.000 abstract description 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000002960 lipid emulsion Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000003934 vacuole Anatomy 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FXLJDRXREUZRIC-BAOOBMCLSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO FXLJDRXREUZRIC-BAOOBMCLSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- -1 triterpene glucoside Chemical class 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009168 Chyluria Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000019137 high fructose diet Nutrition 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a food composition with functions of lowering blood sugar and blood fat and improving fatty liver, belongs to the functional food field, and concretely provides a food composition with functions of lowering blood sugar and blood fat and improving fatty liver and a preparation method therefor. The food composition contains 3-6 parts of roots of kudzu vine, 3-6 parts of polygonatum rhizome, 3-6 parts of raspberries, 2-4 parts of medlars, 2-4 parts of haws, 1-3 parts of platycodon grandiflorum and 1-2 parts of lalang grass rhizome. Experiment research on mice with impaired glucose regulation shows that, the composition can raise sugar tolerance, increase insulin sensitivity, lower fasting blood glucose, lower blood fat and improve fatty liver substantially. The composition can be used for preparation of auxiliary health-care food lowering blood sugar and blood fat and improving fatty liver, and has substantial advantages of no toxic or side effects, high safety and economy and the like.
Description
Technical field
The invention belongs to functional food technical field, be specifically related to a kind of hypoglycemic, reducing blood lipid and improve functional food composition formula and the production method of fatty liver.
Background technology
Raising along with people's living standard, due to the change of people's dietary structure, rhythm of life and the few impact of moving the factors such as life style of sitting that day is becoming tight more, whole world onset diabetes rate increases year by year, has become the fourth-largest disease that causes population in the world death.According to latest data statistics, diabetes mellitus in China crowd is approximately 1.13 hundred million at present, and prediabetes is 4.93 hundred million.IGR (IGR) is the transition state of glycometabolism between normal and diabetes B, is the preliminary stage of diabetes.IGR is carried out to generation, the development that effective intervention could prevent and delay diabetes, delay the complication of capilary and trunk, thereby will obviously reduce crowd's the death rate.Diabetes belong to traditional Chinese medicine " diabete " category, and IGR should be early stage or the commitment of " diabete " mutually.Therefore for deficiency of both qi and yin, the internal resistance of the phlegm stasis of blood, carries out treating a disease by looking into both its root cause and symptoms, to reversing patient's condition, improves insulin resistance very crucial.In IGR crowd, complication is as high fat of blood and fatty live lesions also ubiquity.After Liver fatty deposition, be prone to sugar and absorb extremely, and cause more serious IGR.Therefore regulate high fat of blood and fatty liver, for delaying IGR, to develop into diabetes significant equally simultaneously.
Generally believe at present, although it is slightly disorderly to have there is glycometabolism in the IGR stage, but still can not think a kind of disease, but a kind of sub-health state, if so the method that adopts treatment diabetes is regulated and controled to tend to exceed the proper limits in righting a wrong as taken Western medicine etc., cause the side effects such as hypoglycemia, gastrointestinal reaction.Theoretical according to Traditional Chinese medical theory integration of drinking and medicinal herbs, the present invention is theoretical in conjunction with traditional Chinese medicine and pharmacy, and selection function food carries out rational proportion, forms patent formulation.Formulations composition is integration of drinking and medicinal herbs food, is suitable for every day edible, makes the adjusted blood sugar of Impaired Glucose Regulation and fat metabolism, protection and raising organ function, improves the multiple benefits such as physical function.
Summary of the invention
In the present invention, for the deficiencies in the prior art, propose a kind of food composition that reduces blood sugar, reducing blood lipid and improve fatty liver, effect is remarkable, and has no side effect.
The technical solution adopted for the present invention to solve the technical problems is: this kind of food composition that reduces blood sugar, reducing blood lipid and improve fatty liver, is characterized in that in described food composition that effectively raw material forms and weight proportion is: root of kudzu vine 3-6 part, sealwort 3-6 part, raspberry 3-6 part, matrimony vine 2-4 part, hawthorn 2-4 part, balloonflower root 1-3 part, cogongrass rhizome 1-2 part.
Preferably, the raw material of making this food composition active ingredient forms and weight proportion is: 4 parts of the roots of kudzu vine, 4 parts of sealworts, 4 parts of raspberries, 3 parts of matrimony vines, 3 parts of hawthorn, 2 parts of balloonflower roots, 1 part of cogongrass rhizome.
During proportioning, preferably the described root of kudzu vine, sealwort and raspberry are added by equivalent.
During proportioning, preferably described matrimony vine and hawthorn are added by equivalent.
The present invention also provides the preparation technology of this food composition active ingredient, specifically adopts following steps:
Steps A: by weight the selected root of kudzu vine, sealwort, raspberry, matrimony vine, hawthorn, balloonflower root, cogongrass rhizome, mechanical disintegration, crosses 60 mesh sieves, obtains medicinal material particle;
Step B: add 70% ethanol of 8 times of medicinal material particle weight, ultrasonic wave extracts 30min at 50 ℃, extracts three times, filters merging extract;
Step C: decompression and solvent recovery, temperature, lower than 55 ℃, obtains alcohol extracting paste, is further dried as flour.
Above-mentioned food composition extracts powdered thing can be made into powdery or granular nutrient powder or tablet or capsule.
The root of kudzu vine, taste is sweet, pungent, cool in nature, returns spleen, stomach warp, has and promotes the production of body fluid to quench thirst, and rises the merit of positive antidiarrheal; In < < Sheng Nong's herbal classic > >, just there is the record of " root of kudzu vine smell is sweet flat nontoxic, main quenching one's thirst "; The folk prescription that kudzuvine root juice in < < General Records of Holy Universal Relief > > is quenched one's thirst for treatment, with the root of kudzu vine is clearing heat and detoxicating simply, promote the production of body fluid to quench thirst, moisturize relieving restlessness, invigorating the spleen rises clear, to help body fluid source and defeated cloth.The main component Puerarin of the root of kudzu vine, has and suppresses interior free yl, hypoglycemic and improve microangiopathies texts.
Sealwort, taste is sweet, property is flat, returns spleen, lung, kidney channel.The effect with tonifying spleen moistening lung, supplementing qi and nourishing yin, for nourishing and fit keeping function and treatment suffer from a deficiency of the kidney, the deficiency syndrome of the lung and weakness of the spleen and the stomach disease.Modern pharmacology research is found, contains multiple steroid saponin constituents and Flavonoid substances in sealwort, is conducive to strengthen immunity of organisms, has reducing blood lipid, the hypoglycemic and effect such as delay senility simultaneously.
Raspberry: warm in nature, the sweet acid of taste, flat.Return kidney, urinary bladder channel.Containing organic acid, carbohydrate and vitamin C, filling liver kidney, dwindles just, supporing yang, controlling nocturnal emission with astringent drugs, improving eyesight, consumptive disease.
The fruit of Chinese wolfberry, taste is sweet, property is flat, has the effects such as kidney tonifying, enriching yin, nourishing the liver, improving eyesight, beneficial gas.Modern study finds that the fruit of Chinese wolfberry has anticancer, AFL, hypotensive and promote body to regulate the effects such as immunologic function.Be usually used in improving diabetes, hepatopathy and health care for the aged.
Crataegolic acid is sweet, and merit is arrogated to oneself spleen benefiting and stimulating the appetite, promoting blood circulation to remove blood stasis, the promoting the circulation of qi of reducing phlegm, and the especially kind greasy meat of carburetion is stagnant.Hawthorn energy prevention and cure of cardiovascular disease, has softening blood vessel, hypotensive, reducing blood lipid, improves blood circulation effect.
Balloonflower root taste is arduous, and calmness, analgesia, antipyretic, eliminate the phlegm, and treats laryngopharynx bitterly, and sharp the five internal organs stomach, has hemangiectasis, reducing heart rate, hypoglycemic and reducing blood lipid, inducing diuresis to reduce edema, antiulcer, antiallergy, the effect such as antitumor.Mainly contain multiple triterpene glucoside as ursolic acid, oleanolic acid etc., flavonoids is as compounds such as rutin, large sweet-scented osmanthus grass elements.Modern pharmacological research shows that the composition such as saponin class, flavonoids in plant has the activity of anti-inflammatory.
Cogongrass rhizome: cold in nature, taste is sweet.Clear heat with drugs of sweet flavour and cold nature, the diuresis of promoting the production of body fluid.Often with single or compound treatment difficult urination, blood urine and chyluria, oedema and hepatitis etc.< < herbal classic > > has the record of " the empty win of main internal lesion caused by overexertion, tonifying middle-Jiao and Qi, except extravasated blood, blood close fever and chills, diuresis ".
Visible according to results of animal, food composition of the present invention, after long term administration, is lowering postprandial blood sugar and fasting blood-glucose, and the effect of improving hyperlipemia and fatty liver is remarkable.
Accompanying drawing explanation
Accompanying drawing is murine liver tissue steatosis pathological change figure (oil red O stain, * 200), wherein, and NC: Normal group (upper left); MC: model control group (upper); PC: positive controls (upper right); AMF: dosage group (bottom left) in formula alcohol extract; AHF: formula alcohol extract high dose group (bottom right); →, the red fat that dyes drips.
the specific embodiment
Below by specific embodiment, the present invention is described in detail.Following embodiment, only gives an example for representative of the present invention, should not be construed as limited range of the invention process.Every simple replacement or variation to formula of the present invention, production craft step and condition, all belongs to protection scope of the present invention.
Embodiment 1
Get root of kudzu vine 200g, sealwort 200g, raspberry 200g, matrimony vine 150g, hawthorn 150g, balloonflower root 100g, cogongrass rhizome 50g, mechanical disintegration, crosses 60 mesh sieves.70% ethanol that adds 8 times of medicinal material particle weight, ultrasonic wave extracts 30min at 50 ℃, extracts three times, merges extract, and decompression and solvent recovery, to suitable volumes, obtains alcohol extracting paste, is dried, and makes nutrition powder.
Embodiment 2
Get root of kudzu vine 300g, sealwort 300g, raspberry 300g, matrimony vine 200g, hawthorn 200g, balloonflower root 120g, cogongrass rhizome 60g, mechanical disintegration, crosses 60 mesh sieves.70% ethanol that adds 8 times of medicinal material particle weight, ultrasonic wave extracts 30min at 50 ℃, extracts three times, merges extract, and decompression and solvent recovery, to suitable volumes, obtains alcohol extract thick paste, adds appropriate dextrin, mix, granulation, dry, compacting is in blocks, makes tablet.
Embodiment 3
The Combined food of being prepared by above-described embodiment 1 to gained carries out following pharmacodynamic experiment:
The Combined food alcohol extract dried powder of being prepared by the embodiment of the present invention 1 to gained carries out hypoglycemic, reducing blood lipid and improves fatty liver effect experiment the IGR mouse model of the high fructose diet induced of high fat:
1. experiment material and method
Animal used as test: SPF level ICR mouse, 20-22g, male, Beijing Vital River Experimental Animals Technology Co., Ltd. provides, the quality certification number: SCXK(capital) 2007-0001.Mouse feed composition: carbohydrate 64%, protein 21%, fat 4%, fiber 5%, is purchased from zoopery center, Beijing.Mouse is raised in China Agricultural University's Food Science and nutrition engineering college zoopery center (SPF level).Room ventilation condition is good, normally changes round the clock, and relative humidity is 55 ± 5%, room temperature: 23 ± 2 ℃.
Experimental technique: mouse adaptability was fed after 7 days, and 50 mouse are divided into 5 groups at random,, does grouping as follows: Normal group (NC), gavage 7% Tween-80 solution by 10 every group; Model control group (MC), usings 15% fructose water as unique water source in the time of gavage Fat Emulsion; Melbine positive controls (PC); The embodiment of the present invention 1 is prepared dosage group (AMF) and high dose group (AHF) in the food compositions alcohol extract of gained.Each group is edible conventional feed all, and NC organizes drinking pure water; Except NC group, all the other respectively organize equal gavage Fat Emulsion, using 15% fructose water as unique water source.Fat Emulsion preparation method: lard 50g, cholesterol 1.5g, pig cholate 0.3g, Tween-80 7mL, adds water and is settled to 100mL, is made into Fat Emulsion ,-20 ℃ of preservations.
Every day gavage dosage (in)=amount ÷ body weight (in 60kg) * the weight of animals * 20 times formula (1)
Gavage dosage every day (height)=amount ÷ body weight (in 60kg) * the weight of animals * 30 times formula (2)
The gavage amount of the alcohol extract of formula is calculated with formula (1) and (2), is then diluted with distilled water into the adaptation gavage volume (0.2mL/10g b.w) of mouse, positive controls gavage 0.5g/kg b.w. melbine.
2. measure and observation index
Adaptation is carried out intervention experiment to each group according to above grouping after raising and finishing, and gavage is 10 weeks continuously, within every three days, weigh 1 time, and satellite recanalization dosage.Test and measure sugar tolerance the 9th weekend, test and measure insulin tolerance the 10th weekend.When experiment finishes, fasting 13h after animals administer, does not limit drinking-water, plucks eyeball blood sampling, measures TC, TG, HDL-C, LDL-C and FFA content.Dissect mouse, get after its liver weighs, wherein a part of liver carries out histotomy observation.
2.1. the mensuration of blood sugar
Mouse fasting (can't help water) 13h, cuts tail vein blood, by Johnson & Johnson's blood glucose meter, measures mouse blood sugar, directly reading out data.
2.2. oral glucose tolerance test (OGTT)
Mouse fasting (can't help water) 13h, each is organized its mouse oral and gives 2.0g/kg b.w. glucose solution.In 120min subsequently, at 0min, 30min, 60min, 120min, cut tail vein blood respectively, blood glucose meter is measured blood sugar.Area under glucose tolerance curve (AUC) adopts trapezoidal method to calculate:
TG-AUC=0.25 * (0min blood sugar+30min blood sugar)+0.25 * (30min blood sugar+60min blood sugar)+0.5 * (60min blood sugar+120min blood sugar)
2.3. insulin tolerance test (ITT)
Mouse fasting (can't help water) 4h, each organizes mouse peritoneal injection 0.6IU/kg b.w. short-acting insulin.In 90min subsequently, at 0min, 30min, 50min, 70min, 90min, cut tail vein blood respectively, blood glucose meter is measured blood sugar.
2.4. the mensuration of blood fat
Mouse fasting (can't help water) 13h, in the blood sampling of eyeball rear vein beard, in the centrifugal 15min of 4000g, separation of serum, measures TC, TG, LDL-C, HDL-C and FFA.
3. experimental result:
IGR mouse to the induction of Fat Emulsion associating fructose is intervened, and the sugar tolerance result after 9 weeks is as shown in table 1.
Table 1. is intervened the sugar tolerance (n=10) of mouse after 9 weeks
Note: with NC comparison, #P<0.05, ##P<0.01; With MC comparison, * P<0.05, * * P<0.01.
From table 1, model control group shows associating IGT after 9 weeks in diet induced, and fasting blood-glucose raises 28.6% than Normal group, has utmost point significant difference, and its AUC and Normal group relatively exist utmost point significant difference.Melbine reduces the fasting blood-glucose of mouse, has improved sugar tolerance, illustrates that antidiabetic drug shows lasting effectively preventive effect to mouse IGR.More all there were significant differences for the alcohol extract high dose group each point blood sugar of formula and AUC and model control group, reduce respectively 24.4%, 29.3%, 29.5%, 19.3% and 23.0%, wherein dosage group mouse fasting blood-glucose, 30min blood sugar and AUC reduce, and more all have utmost point significant difference with model control group.Relatively 9 weeks rear formula extracts of gavage found that the intervention of mouse IGR: the alcohol extract high dose of formula reduces fasting blood-glucose when improving IGT, lasting to the preventive effect of mouse IGR, is dose-effect relationship.
Formula extract is intervened and is carried out ITT on the 10th week IGR mouse, the results are shown in Table 2:
Table 2. is intervened the insulin tolerance (n=10) of mouse after 10 weeks
Note: with NC comparison, ##P<0.01; With MC comparison, * P<0.05, * * P<0.01.
From table 2, after model control group mouse peritoneal insulin injection, blood sugar declines, during 50min, blood sugar touches the bottom, blood sugar bottom out subsequently, during 90min, blood sugar reaches 63.6% of initial blood sugar, initial blood sugar respectively than Normal group mouse high 52.8% and 66.7%, has utmost point significant difference with 90min blood sugar.The initial blood sugar of positive controls declines 20.0% and 28.6% than model control group respectively with 90min blood sugar, and there were significant differences.Formula extract intervention group initial blood sugar is lower than model control group, and has significant difference; The alcohol extract high dose group 70min of formula and 90min blood sugar are all lower than model control group (P<0.05), and 90min blood sugar only reaches 32.1% of initial blood sugar; In formula alcohol extract, dosage group 70min blood sugar and model control group do not have difference, and the alcohol extract of filling a prescription is as seen improving in the effect of mouse islets element sensitiveness, and high dose is better than middle dosage, amount effect relationship.
Formula extract is intervened and is carried out lipid determination on the 10th week IGR mouse, the results are shown in Table 3.After model control group diet induced 10 weeks, mice serum LDL-C, TC and FFA level are significantly higher than Normal group.Melbine makes serum LDL-C and TC content have the trend of rising.In formula alcohol extract, dosage reduces FFA level, and high dose group reduces TC, TG and FFA level.
Table 3. is intervened the blood lipids index (n=10) of mouse after 10 weeks
Note: with NC comparison, ##P<0.01; With MC comparison, * P<0.05, * * P<0.01.
Through test in 10 weeks, each carried out oil red O stain after organizing mouse liver freezing microtome section, observed hepatic tissue fat deposition situation, and result as shown in the figure.Visible indivedual fat vacuoles not of uniform size only in Normal group liver cell, are negative.In model control group mouse liver cell, the visible little red fat vacuole that dyes of diffusivity, illustrates that fat deposition degree is serious in hepatic tissue, severe fatty liver.The visible red fat vacuole that dyes of diffusivity in positive controls mouse cell, and fat drop is larger, illustrates that melbine does not have obvious inhibitory action to fatty degeneration of liver.The visible little red fat vacuole that dyes in the about 30%-40% liver cell of dosage group mouse in formula alcohol extract, slight fatty liver; The little red fat vacuole that dyes in the visible about 20%-30% liver cell of hepatic tissue of formula alcohol extract high dose group mouse, hepatic cell fattydegeneration.Alcohol extract is dose-effect relationship to suppressing fat deposition in hepatic tissue, and high dose is better than middle dosage.This result of study alcohol extract that shows to fill a prescription has remarkable minimizing mouse liver fat deposition, prevents and alleviates the function that fatty liver forms.
Result is visible from the above mentioned, and this Combined food formula of the present invention can play good reduction blood sugar, reduce blood fat, alleviates the effect of fatty liver simultaneously.
Claims (6)
1. hypoglycemic, reducing blood lipid and improve the food composition of fatty liver, the raw material that it is characterized in that active ingredient in described food composition forms and weight proportion is: root of kudzu vine 3-6 part, sealwort 3-6 part, raspberry 3-6 part, matrimony vine 2-4 part, hawthorn 2-4 part, balloonflower root 1-3 part, cogongrass rhizome 1-2 part.
2. a kind of hypoglycemic, reducing blood lipid according to claim 1 and improve the food composition of fatty liver, the raw material that it is characterized in that active ingredient in described food composition forms and weight proportion is: 4 parts of the roots of kudzu vine, 4 parts of sealworts, 4 parts of raspberries, 3 parts of matrimony vines, 3 parts of hawthorn, 2 parts of balloonflower roots, 1 part of cogongrass rhizome.
3. a kind of hypoglycemic, reducing blood lipid according to claim 1 and improve the food composition of fatty liver, is characterized in that: the described root of kudzu vine, sealwort and raspberry add by equivalent.
4. a kind of hypoglycemic, reducing blood lipid according to claim 1 and improve the food composition of fatty liver, is characterized in that: described matrimony vine and hawthorn add by equivalent.
5. according to a kind of hypoglycemic, the reducing blood lipid described in claim 1-4 any one with improve the food composition of fatty liver, it is characterized in that the preparation technology of active ingredient comprises the steps:
Steps A: by weight the selected root of kudzu vine, sealwort, raspberry, matrimony vine, hawthorn, balloonflower root, cogongrass rhizome, mechanical disintegration, crosses 60 mesh sieves, obtains medicinal material particle;
Step B: add 70% ethanol of 8 times of medicinal material particle weight, ultrasonic wave extracts 30min at 50 ℃, extracts three times, filters merging extract;
Step C: decompression and solvent recovery, temperature, lower than 55 ℃, obtains alcohol extracting paste, is further dried as flour.
6. a kind of hypoglycemic, reducing blood lipid according to claim 5 and improve the food composition of fatty liver, is characterized in that described food composition to make powdery or granular nutrient powder or tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310469837.6A CN103637179B (en) | 2013-10-10 | 2013-10-10 | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310469837.6A CN103637179B (en) | 2013-10-10 | 2013-10-10 | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103637179A true CN103637179A (en) | 2014-03-19 |
| CN103637179B CN103637179B (en) | 2015-02-18 |
Family
ID=50242586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310469837.6A Expired - Fee Related CN103637179B (en) | 2013-10-10 | 2013-10-10 | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103637179B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104095234A (en) * | 2014-07-04 | 2014-10-15 | 凯泽（武汉）健康管理有限公司 | Functional food for conditioning fatty liver |
| CN107625129A (en) * | 2017-09-06 | 2018-01-26 | 如皋市滋生堂生物科技有限公司 | A kind of hypoglycemic and the health food and its production method of reducing blood lipid |
| CN110506822A (en) * | 2019-10-10 | 2019-11-29 | 湖北民族大学 | A kind of rhizoma polygonati Poria cocos teabag drink and preparation method thereof |
| CN114668813A (en) * | 2022-01-24 | 2022-06-28 | 安徽富韵生物科技有限公司 | Application of polygonatum sibiricum and nitraria tangutorum composition in regulating blood sugar and blood fat |
| CN114831197A (en) * | 2022-05-23 | 2022-08-02 | 湖南楚茗茶业有限公司 | Composite dark tea and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899446A (en) * | 2006-07-05 | 2007-01-24 | 吉林农业大学 | Wolfberry fruit tablet health product and its preparing method |
| CN101112525A (en) * | 2006-07-26 | 2008-01-30 | 郁华军 | Health products having functions of invigorating qi and blood and restoring consciousness and refreshing oneself |
| CN101263901A (en) * | 2008-04-29 | 2008-09-17 | 刘跃明 | Plant health care wine |
| CN102551140A (en) * | 2012-01-13 | 2012-07-11 | 唐新秀 | Sobering and liver-protecting kudzu vine root beverage |
-
2013
- 2013-10-10 CN CN201310469837.6A patent/CN103637179B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899446A (en) * | 2006-07-05 | 2007-01-24 | 吉林农业大学 | Wolfberry fruit tablet health product and its preparing method |
| CN101112525A (en) * | 2006-07-26 | 2008-01-30 | 郁华军 | Health products having functions of invigorating qi and blood and restoring consciousness and refreshing oneself |
| CN101263901A (en) * | 2008-04-29 | 2008-09-17 | 刘跃明 | Plant health care wine |
| CN102551140A (en) * | 2012-01-13 | 2012-07-11 | 唐新秀 | Sobering and liver-protecting kudzu vine root beverage |
Non-Patent Citations (1)
| Title |
|---|
| 王慧芳 等: "药食两用中药降血糖作用研究进展", 《中国煤炭工业医学杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104095234A (en) * | 2014-07-04 | 2014-10-15 | 凯泽（武汉）健康管理有限公司 | Functional food for conditioning fatty liver |
| CN104095234B (en) * | 2014-07-04 | 2015-10-28 | 凯泽（武汉）健康管理有限公司 | A kind of functional food nursing one's health fatty liver |
| CN107625129A (en) * | 2017-09-06 | 2018-01-26 | 如皋市滋生堂生物科技有限公司 | A kind of hypoglycemic and the health food and its production method of reducing blood lipid |
| CN110506822A (en) * | 2019-10-10 | 2019-11-29 | 湖北民族大学 | A kind of rhizoma polygonati Poria cocos teabag drink and preparation method thereof |
| CN114668813A (en) * | 2022-01-24 | 2022-06-28 | 安徽富韵生物科技有限公司 | Application of polygonatum sibiricum and nitraria tangutorum composition in regulating blood sugar and blood fat |
| CN114831197A (en) * | 2022-05-23 | 2022-08-02 | 湖南楚茗茶业有限公司 | Composite dark tea and preparation method and application thereof |
| CN114831197B (en) * | 2022-05-23 | 2023-08-29 | 湖南楚茗茶业有限公司 | Composite black tea and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103637179B (en) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN103285231A (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN103749822B (en) | A kind of fruit of glossy privet hypertension and hyperlipemia health protection tea and preparation method thereof | |
| CN107822040A (en) | A kind of preparation method of rhizoma zingiberis cinnamon health care jelly | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN103749818B (en) | A kind of sealwort hypoglycemic health protection tea and preparation method thereof | |
| CN103479878A (en) | Medicated tea for conditioning and treating diabetes | |
| CN103223111A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN105124078A (en) | Gardenia blood-glucose-reducing and lipid-reducing healthcare tea and preparing method thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN104474472B (en) | Buccal lozenge of lectuce tea and its production method with three high drop effect | |
| CN103749819B (en) | Fructus Corni health protection tea of a kind of hypoglycemic and preparation method thereof | |
| CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN104887760A (en) | Ganoderma spore powder wine and preparation method thereof | |
| CN107625129A (en) | A kind of hypoglycemic and the health food and its production method of reducing blood lipid | |
| CN103550505A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency type diabetes | |
| CN104606570A (en) | Consumptive thirst tea substitute drink suitable for diabetes patients and preparation method of consumptive thirst tea substitute drink | |
| CN103191297B (en) | Traditional Chinese medicine composition for treating male infertility and preparation method thereof | |
| CN103599211B (en) | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof | |
| CN103585434B (en) | Traditional Chinese medicine composition for treating anemia | |
| CN103082298A (en) | Health-care food for reducing blood glucose in assisted mode and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150218 Termination date: 20161010 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |